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C h a p t e r  7
Chopter 7 Clycogen Storage Disease type 1 is caused by a deficient function of glu-
cose-6-phosphatase.  In  the most  l ike ly  model  for  the funct ion o f  g lucose-6-phos-
phatase,  g lucose-6-phosphatase cons is ts  o f  a  cata ly t ic  subuni t ,  g lucose-6-
phosphatase,  wi th  one or  more membrane t ranspor ters .  The cata ly t ic  subuni t  is  s i tu-
a ted on the lumina l  sur face of  the endoplasmat ic  re t icu lum to  which subst ra tes ga in
access by t ranspor ter (s) .  CSD-Ia  is  caused by defects  in  the cata ly t ic  un i t ,  the actua l
g lucose-6-phosphatase.  Defects  o f  the t ranspor ters  were named CSD-1 b,  CSD-1c
and CSD-1d and were ident i f ied by def ic ient  C6Pase act iv i t i ty  in  a  hepat ic  microso-
mal  preparat ion,  which increases af ter  d is rupt ion o f  l i ver  microsomes by a  detergent .
More recent  molecu lar  genet ic  s tud ies have shown that  pat ients  who had been
d iagnosed  as  CSD-1  b ,  1c  and  t he  pu ta t i ve  1d ,  a l l  had ,  some  even  i den t i ca l ,  mu ta -
t ions in  the gene encoding the C6P t ranspor ter .  Th is  was cons is tent  wi th  the c l in ica l
f ind ings as CSD-1 can be d iv ided in  two c l in ica l  phenotypes.  CSD-1a pat ients  have
>class ica l=  s igns and symptoms (hepatomegaly ,  growth re tardat ion,  osteopenia ,  k id-
ney en largement ,  hypoglycaemia,  hyper lac tac idaemia,  hyper l ip idaemia nd hyper-
ur icaemia) .  CSD-1 b pat ients  have in  addi t ion neut ropenia ,  neut rophi l  dysfunct ion
and in f lammatory  bowel  d isease ( lBD) .  However ,  i t  has been descr ibed that  some
pat ients  wi th  CSD-1a who are homozygous for  the C188R mutat ion a lso have neu-
t ropenia  and neut rophi l  dysfunct ion.  Fur thermore,  a s ing le  CSD- lc  pat ient  has been
repor ted wi thout  mutat ions in  the C6P t ranspor ter  gene suggest ing again  the ex is-
tence of  a  d is t inc t  CSD-1c locus.  A mutat ion in  the promotor  reg ion may,  however ,
a lso be respons ib le  for  the phenotype.  In  conc lus ion,  despi te  the fact  that  a  lo t  o f
progress has been made,  the cont roversy about  the exact  work ing mechanism of
the g lucose-6-phoshatase complex s t i l l  remains.  For  pract ica l  d iagnost ic  purposes
nowadays mutat ion analys is  is  in  most  pat ients  suf f ic ient .
The c l in ica l  descr ip t ion o f  CSD-1b is  so far  on ly  known f rom case repor ts .  The f i rs t
a im of  th is  thes is  is  to  increase knowledge of  the c l in ica l  p ic ture o f  CSD-1 b.  CSD-1b
is  a  rare d isease,  so that  the inc idence,  the sever i ty  and the course of  neut ropenia ,
neut rophi l  dysfunct ion and in f lammatory  bowel  d isease ( lBD)  in  CSD-1b were inves-
t igated as part of a col laborative European Study on Clycogen Storage Dísease type
1 (ESCSD).  Resul ts  o Í  th is  s tudy are descr ibed in  chapter  2 .
A re t rospect ive reg is t ry  was estab l ished in  12 European count r ies  that  inc luded a l l
CSD- l  pat ients  known at  the centers  born f rom 1960 upto 1995.  Out  o f  a  to ta l  o f
288 CSD-I  pat ients ,  57 (19.8o/o)  had CSD-1b who form the bas is  o f  th is  s tudy.
Neutropenia  (def ined as an absolu te  neut rophi l  count  <  1  .0x lOe/ l )  was found in
54 pat ients .  In  64 o/o  o f  the pat ients  neut ropenia  was documented before the age of
1 year, but in 18 o/o of the patients neutropenia was f irst noted between the age of
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6-9 years .  Neut ropenia  was pers is tent  in  5  pat ients  and in termi t tent ,  w i thout  any
c lear  cyc l ica l  course in  45.  Neut rophi l  funct ion was invest igated in  18 pat ients  wi th
neut rooenia  nd was abnormal  in  a l l .
Perioral infect ions were reported in 37 patients, perianal infect ions in 27 patients
and prot racted d iar rhoea in  23 pat ients .  F ind ings on co lonoscopy and rad io log ica l
s tud ies per formed in  10 of  20 pat ients  suspected to  have lBD,  were abnormal  in  a l l .
A l l  pat ients  wi th  lBD,  per iora l  and per iana l  in fect ions had neut ropenia .
In  conc lus ion,  in termi t tent  severe neut ropenia  is  f requent ly  found in  pat ients  wi th
CSD-1b.  The age of  onset  o f  neut ropenia  in  CSD-1b is  apparent ly  b imodal .
The s tudy a lso ind icates that  IBD in  CSD-1b is  underd iagnosed,  up to  77o/o f  the
pat ients  s tud ied had ev idence of  lBD,  a l l  o f  whom had neut ropenia .  These f ind ings
suppor t  the not ion that  neut ropenia  nd or  neut rophi l  dysfunct ion in  CSD-1b and
IBD are causal ly  re la ted.
Pat ients  wi th  Clycogen Storage Disease type 1b (CSD-1b)  have neut ropenia  and
neut rophi l  dysfunct ion that  pred ispose to  f requent  in fect ions and in f lammatory
bowel disease ( lBD), for which since 1 989 granulocyte colony-st imulat ing factor
(CCSF) is  g iven.  Th is  t reatment  resu l ted,  accord ing severa l  case repor ts ,  in  an
increase of  the neut rophi l  count  and regress ion of  the lBD,  but  th is  e f fec t  has not
been evaluated systematical ly. Some of the potential complications of treatment
wi th  CCSF,  as osteopenia  and leukemia,  cou ld  be espec ia l ly  harmfu l  to  CSD-Ib
patients. The second aim of this thesis is to evaluate the benefi ts and hazards of
CCSF t reatment  in  CSD-1b in  order  to  def ine the va lue of  CCSF t reatment  in  CSD-
' lb. These aspects were also studied as part of the ESCSD and the results are
described in chopter 3.
Unglycosy la ted CCSF was g iven to  18 pat ients  o f  the 5Z pat ients  ment ioned above.
The median age of start ing therapy was 8 years, the longest duration of therapy was
7 years. The used doses varied between 2-10 mcglkg, with a frequency from dai ly to
twice per week. Severe neutropenia (defined as an absolute neutrophi l  count
< 0 .5x1Oe/ l )  was found in  49 pat ients .  In  unt reated pat ients  a  s ign i f icant  decrease of
hemoglob in ,  p la te le t  counts  and leucocyte counts  wi th  increas ing age (p<0.032,
p<0.04 and p<0.001 respect ive ly)  was noted,  whereas neut rophi l  counts  remained
low but  s tab le  wi th  increas ing age.  In  9  pat ients  who were t reated longer  then
1 year ,  median neut rophi l  counts  increased s ign i f icant ly  and s imul taneous ly  median
leucocyte counts and platelet counts decreased signif icantly. ln al l  patients treated,
the number and severity of infect ions decreased and the severity of IBD improved
subject ive ly .  The most  ser ious compl icat ion o f  CCSF t reatment  was marked
splenomeg aly (4 patients).
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In  conc lus ion in  th is  re t rospect ive s tudy regard ing the ef fec t  o f  CCSF in  CSD-1b,  a
s ign i f icant  hemato log ica l  e f fec t  was documented and a sub ject ive improvement  o Í
in fect ions and lBD.  In  v iew of  the uncer ta in ty  prospect ive cont ro l led t r ia ls  seem war-
ranted to  c lar i fy  the ind icat ion for  the use of  CCSF in  th is  d isease.
The exact  pathogenes is  o f  the neut ropenia  and neut rophi l  dysfunct ion in  CSD- l  is
s t i l l  unknown.  In  the ESCSD invest igat ion o f  the resp i ra tory  burs t  in  neut rophi ls  was
in  a l l  invest igated pat ients  abnormal  (chapter  2) .  Fur thermore the resu l ts  o f  the
study conf i rmed the wide var ie ty  o f  d is turbed neut rophi l  funct ion.
In  the rest ing s ta te ,  neut rophi ls  are metabol ica l ly  inact ive,  the t rans i t ion to  an act ive
state, is associated with a marked increase in metabolic act ivi ty termed the 'metabol-
ic '  or  ' resp i ra tory '  burs t .  Cenera l ly  i t  is  assumed that  neut rophi ls  are dependent  for
the i r  energy supply  on the mobi l isa t ion o f  in t race l lu lar  g lycogen s torage or  on ext ra-
ce l lu lar  g lucose.  To ga in  more ins ight  in  the neut rophi l  dysfunct ion in  CSD- '1 ,  the
effect of addit ion of glucose on neutrophi l  function was studied in vitro. This was
f i rs t  s tud ied in  neut rophi ls  o f  pat ients  wi th  CSD-1b,  which is  descr ibed in  chapter
4 . 1  .
In  th is  s tudy,  we estab l ished exper imenta l  condi t ions to  show the s t imulat ion o f  the
neut rophi l  resp i ra tory  burs t  by  ext race l lu lar  g lucose.  Wi th  PMA as s t imulus o f  the
resp i ra tory  burs t ,  the act iv i ty  o f  the n icot inamide adenine d inuc leot ide phosphate
ox idase in  CSD-1b neut rophi ls  hard ly  increased upon addi t ion o f  g lucose.  In  cont ro l
and CSD-1a neut rophi ls ,  however ,  a  c lear  increase was observed.  The lack o f
response to  ext race l lu lar  g lucose in  CSD-1b neut rophi ls  was corre la ted wi th  the
inabi l i ty  to  ra ise in t race l lu lar  C6P leve ls  upon g lucose addi t ion.
In  conc lus ion upon s t imulat ion o f  the resp i ra tory  burs t  in  the presence of  g lucose
neut rophi ls  o f  pat ients  wi th  CSD-Ib show a decreased in t race l lu lar  C6P concent ra-
t ion and a decreased superox ide product ion.
Recently synthetic chlorogenic acid derivatives (a.o. 54048) have been proven to be
inh ib i tors  o f  the C6P- t ranspor ter  in  l iver  and k idney,  thereby potent ia l ly  mimick ing
CSD-1b.  The same exper iments  as descr ibed in  chapter  4 .1  were repeated wi th  nor-
mal  neut rophi ls  in  which the C6P-t ranspor ter  was inh ib i ted wi th  54048.  Th is  in
order  to  invest igate  whether  acute inh ib i t ion o f  the C6Ptranspor ter  would  resu l t  in  a
decreased in t race l lu lar  C6P concent ra t ion and a decreased superox ide product ion
upon s t imulat ion o f  the resp i ra tory  burs t  as  is  found in  CSD-Ib  neut rophi ls .  The
results of these experiments are described in chapter 4.2.
ln  normal  neut rophi ls  incubated wi th  54048,  s t imulat ion o f  the resp i ra tory  burs t  by
PMA resu l ted in  increased in t race l lu lar  C6P concent ra t ions and enhanced suoerox-
ide product ion.  In  unst imulated normal  neut rophi ls  increas ing concent ra t ions o f g lu-
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cose in  the medium resu l ted in  increas ing in t race l lu lar  C6P concent ra t ions,  which
was not affected by the presence of 54048.
Thus, acute inhibit ion of the C6Ptransporter does not negatively affect the respirato-
ry  burs t  as  is  seen in  the chron ic  C6Ptranspor ter  dysfunct iona l  CSD- lb  neut rophi ls .
The neutrophi l  dysfunction in CSD-1b may be caused by a factor dif ferent from the
C6Ptransporter deficiency i tself ,  which might be a decreased activi ty of hexokinase.
In the European Study on Clycogen Storage Disease diarrhoea was reported in 35olo
of  the CSD-1a pat ients  and in  55o/o f  the CSD-Ib oat ients .  The cause of  th is  d iar -
rhoea is unknown, although several hypotheses have been postulated: disturbed
intestinal glucose absorption leading to osmotic diarrhoea, persorption of corn
starch lead ing to  in f lammat ion,  and d is turbed in test ina l  absorpt ion in  genera l  as  a
result of intest inal glycogen storage. None of the hypotheses has thus far been con-
f irmed, but the glucose-6-phosphatase complex is expressed in enterocytes. Apart
f rom these causes,  d iar rhoea in  CSD- ' Ib  pat ients  might  a lso be re la ted to  the IBD
found in  these pat ients .  To detect  a  common cause for  chron ic  d iar rhoea in  CSD-1
invest igat ions on in test ina l  funct ions and morphology in  pat ients  wi th  CSD-1a and
CSD-lb, were performed. Results of this study are described in chapter 5.
Mucosal barr ier function was investigated by excretion of faecal a1-anti trypsine, a
marker  for  mucosal  in tegr i ty  and in f lammat ion.  Increased faecal  a1-ant i t ryps ine
excret ion,  combined wi th  in f lammat ion in  the co lonbiops ies,  was found in  a l l  CSD-
1b pat ients  wi th  d iar rhoea.  Faecal  a1-ant i t ryps ine was normal  in  a l l  CSD-1a pat ients ,
whether  wi th  or  wi thout  d iar rhoea.  In  a l l  CSD-1b pat ients  faeca l  a1-ant i t ryps ine nor-
mal ised dur ing CCSF t reatment ,  accompanied by d isappearance of  in f lammat ion in
the co lonbiops ies and reso lv ing of  d iar rhoea.  Thus,  faeca l  a1-ant i t ryps ine seems a
re l iab le  marker  for  IBD act iv i ty  in  CSD- ' lb .
Mucosal digestive function was investigated by measuring the fat absorption coeff i-
cient and faecal chymotrypsine excretion. Mild abnormal fat absorption was found
both in  some CSD-1a and CSD-1 b pat ients ,  however  not  in  pat ients  wi th  compla in ts
of  d iar rhoea.
Mucosal absorptive function was investigated by expiratory H2 concentrat ions, a
diagnostic sign for 'non absorbed' carbohydrates present in the colon. One of the
hal lmarks o f  t reatment  o f  CSD-1,  is  the d ie t  w i th  s low re leas ing carbohydrates,  usu-
al ly raw cornstarch. After intake of 1 .59/kg raw cornstarch al l  investigated CSD-1a
patients showed normal expiratory H2 concentrat ions, suggesting a good carbohy-
drate absorption. Furthermore, in the present study persorption of cornstarch to the
urine could not be detected, neither in patients with, nor in patients without diar-
rhoea. The diet with cornstarch seems thus, general ly well  tolerated.
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Al l  co lonbiops ies were h is to log ica l  examinated on the presence of  g lycogen or  amy-
lo id .  In  CSD-1 g lycogen s torage has been prev ious ly  repor ted in  the gut ,  espec ia l ly
in  the prox imal  je junum. Fur thermore a case of  amylo idos is  re la ted hear t  fa i lu re  in
CSD-1a was repor ted and systemic  amylo idos is  is  a lso a  known compl icat ion o f  lBD.
In  the present  s tudy,  however ,  ne i ther  g lycogen nor  amylo id  was found in  the co lon
bioos ies.
In  conc lus ion wi th  in test ina l  invest igat ions presented in  th is  s tudy no common
cause for  d iar rhoea in  CSD-1 was found.  ln  CSD-1b loss o f  mucosal  bar r ier  funct ion
due to  in f lammat ion seems to  be the main cause.  Th is  is  most  l ike ly  re la ted to  d is-
t u rbed  neu t roph i l  f unc t i on .  Whe the r  ano the r  cause  i n  CSD-1a  and  i n  CSD-1  b  i s
invo lved,  re la ted to  the d is turbed funct ion o f  g lucose-6-phosphatase in  the entero-
cyte, remains to be investigated.
As a genera l  conc lus ion based on the resu l ts  o f  a l l  s tud ies descr ibed in  th is  thes is ,
gu ide l ines for  fo l low-up and t reatment  o f  CSD-1b were postu la ted and descr ibed in
chapter 6.
These gu ide l ines are in  addi t ion to  the genera l  gu ide l ines (not  summar ized here)  for
CSD- l  and are meant  for  pat ients  wi th  neut ropenia  nd neut rophi l  dysfunct ion.  The
quide l ines are summar ised in  a  tab le  in  chapter  6 .
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